HUP0102292A2 - Szubsztituált dioxo-tiazolidin-származékok, eljárás előállításukra és gyógyszerészeti felhasználásuk - Google Patents

Szubsztituált dioxo-tiazolidin-származékok, eljárás előállításukra és gyógyszerészeti felhasználásuk

Info

Publication number
HUP0102292A2
HUP0102292A2 HU0102292A HUP0102292A HUP0102292A2 HU P0102292 A2 HUP0102292 A2 HU P0102292A2 HU 0102292 A HU0102292 A HU 0102292A HU P0102292 A HUP0102292 A HU P0102292A HU P0102292 A2 HUP0102292 A2 HU P0102292A2
Authority
HU
Hungary
Prior art keywords
hydrate
produces
preparation
pharmaceutical use
results
Prior art date
Application number
HU0102292A
Other languages
English (en)
Inventor
Bernadette Marie Choudary
Ian Robert Lynch
Michael John Sasse
Original Assignee
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc. filed Critical Smithkline Beecham Plc.
Publication of HUP0102292A2 publication Critical patent/HUP0102292A2/hu
Publication of HUP0102292A3 publication Critical patent/HUP0102292A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}- benzil]-2,4-dioxo-tiazolidin-maleinsav-sónak egy hidrátja vonatkozik, amelyreaz jellemző, hogy (i) 0,3-0,6 mólekvivalens mennyiségű vizettartalmaz; és (ii) olyan infravörös spektrumot eredményez, amely akövetkező hullámszámoknál tartalmaz csúcsokat: 1757, 1331, 1290, 1211és 767cm- l; és/vagy (iii) olyan Raman-spektrumot eredményez, amely akövetkező hullámszámoknál tartalmaz csúcsokat: 1758, 1610, 1394, 1316és 1289 cm-1; és/vagy (iv) szilárd állapotban egy olyan magmágnesesrezonanciaspektrumot eredményez, amely lényegében a leírás 1.táblázatában felsorolt kémiai eltolódásokat tartalmazza; és/vagy (v)lényegében a 4. ábrán bemutatott por-röntgendiffrakciós (XRPD) képeteredményez. A találmány kiterjed a hidrát előállítási eljárására,valamint gyógyászati alkalmazására is. Ó
HU0102292A 1997-12-16 1998-12-14 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use HUP0102292A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (2)

Publication Number Publication Date
HUP0102292A2 true HUP0102292A2 (hu) 2002-05-29
HUP0102292A3 HUP0102292A3 (en) 2003-12-29

Family

ID=10823691

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102292A HUP0102292A3 (en) 1997-12-16 1998-12-14 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use

Country Status (37)

Country Link
US (4) US20020133016A1 (hu)
EP (1) EP1042321A1 (hu)
JP (1) JP2002508371A (hu)
KR (1) KR100549141B1 (hu)
CN (3) CN101318957A (hu)
AP (1) AP1363A (hu)
AR (2) AR017211A1 (hu)
AU (2) AU2272299A (hu)
BG (1) BG64850B1 (hu)
BR (1) BR9813598A (hu)
CA (1) CA2314967A1 (hu)
CO (1) CO4990943A1 (hu)
CZ (1) CZ300081B6 (hu)
DZ (1) DZ2679A1 (hu)
EA (1) EA002833B1 (hu)
EG (1) EG22250A (hu)
GB (1) GB9726563D0 (hu)
HR (1) HRP20000404A2 (hu)
HU (1) HUP0102292A3 (hu)
ID (1) ID24714A (hu)
IL (2) IL160847A0 (hu)
MA (1) MA26581A1 (hu)
MY (1) MY128573A (hu)
NO (1) NO317255B1 (hu)
NZ (1) NZ504703A (hu)
OA (1) OA11900A (hu)
PE (1) PE20000125A1 (hu)
PL (1) PL341213A1 (hu)
RS (1) RS50080B (hu)
SA (1) SA99200200B1 (hu)
SK (1) SK286422B6 (hu)
TR (2) TR200001793T2 (hu)
TW (1) TW487709B (hu)
UA (1) UA66821C2 (hu)
UY (2) UY25309A1 (hu)
WO (1) WO1999031093A1 (hu)
ZA (1) ZA9811504B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
KR100744359B1 (ko) * 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
TR200103060T2 (tr) * 1999-04-23 2002-05-21 Smithkline Beecham P. L. C. Yeni farmasötik maddeler
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
CA2426117A1 (en) 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
CN101318956A (zh) 2008-12-10
HUP0102292A3 (en) 2003-12-29
CN1285831A (zh) 2001-02-28
EP1042321A1 (en) 2000-10-11
CZ300081B6 (cs) 2009-01-28
TR200001793T2 (tr) 2000-10-23
RS50080B (sr) 2009-01-22
US20050288513A1 (en) 2005-12-29
BG64850B1 (bg) 2006-06-30
PE20000125A1 (es) 2000-03-03
JP2002508371A (ja) 2002-03-19
DZ2679A1 (fr) 2003-03-29
AU2753802A (en) 2002-05-16
ZA9811504B (en) 2000-06-15
GB9726563D0 (en) 1998-02-11
UA66821C2 (uk) 2004-06-15
HRP20000404A2 (en) 2000-12-31
AU770818B2 (en) 2004-03-04
BR9813598A (pt) 2000-10-10
US20020133016A1 (en) 2002-09-19
TW487709B (en) 2002-05-21
YU36400A (sh) 2003-12-31
AU2272299A (en) 1999-07-05
OA11900A (en) 2006-04-10
NO317255B1 (no) 2004-09-27
UY25306A1 (es) 2000-12-29
CN101318957A (zh) 2008-12-10
SK286422B6 (sk) 2008-09-05
IL160847A0 (en) 2004-08-31
EG22250A (en) 2002-11-30
NO20003070L (no) 2000-06-15
TR199802624A3 (tr) 1999-10-21
ID24714A (id) 2000-08-03
UY25309A1 (es) 1999-07-19
EA200000656A1 (ru) 2000-12-25
BG104606A (en) 2001-02-28
IL136425A (en) 2004-08-31
SA99200200B1 (ar) 2006-11-11
CO4990943A1 (es) 2000-12-26
US20030139604A1 (en) 2003-07-24
AP2000001829A0 (en) 2000-06-30
PL341213A1 (en) 2001-03-26
NZ504703A (en) 2002-12-20
SK9182000A3 (en) 2000-12-11
CA2314967A1 (en) 1999-06-24
US20070037859A1 (en) 2007-02-15
MA26581A1 (fr) 2004-12-20
AP1363A (en) 2005-01-21
IL136425A0 (en) 2001-06-14
NO20003070D0 (no) 2000-06-15
WO1999031093A1 (en) 1999-06-24
CZ20002206A3 (cs) 2000-12-13
MY128573A (en) 2007-02-28
KR20010033140A (ko) 2001-04-25
TR199802624A2 (xx) 1999-10-21
US7368574B2 (en) 2008-05-06
EA002833B1 (ru) 2002-10-31
KR100549141B1 (ko) 2006-02-03
AR016161A1 (es) 2001-06-20
AR017211A1 (es) 2001-08-22

Similar Documents

Publication Publication Date Title
HUP0102292A2 (hu) Szubsztituált dioxo-tiazolidin-származékok, eljárás előállításukra és gyógyszerészeti felhasználásuk
HUP0300158A2 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
HUP0102084A2 (hu) Kinolinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0100509A2 (hu) Gyógyszerhatóanyagként alkalmazható 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrát, eljárás az előállításukra és gyógyászati alkalmazása
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
MX9604020A (es) Arilalquildiazinonas.
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
HUP0102334A2 (hu) Paroxetin-metánszulfonát, eljárás az előállítására, valamint a vegyületet tartalmazó gyógyszerkészítmények
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
HU913193D0 (en) 17betha-substituted 4-aza-5alpha-androstane-3-on derivatives, process for their production and for the production of medical preparations containing them
HUP0101192A2 (hu) Cikloalkénszármazékok, előállításuk és alkalmazásuk
HUP0100500A2 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása
EA200101119A1 (ru) Новый фармацевтический препарат
YU75301A (sh) Polimorfni oblik soli maleinske kiseline i 5-(4-(2-(n-metil- n-(2-piridil)amino)etoksi)benzil)-tiazolidin-2,4-diona
AU2797695A (en) Thiazolidine derivatives, their preparation and drugs containing same
AR023750A1 (es) Un proceso para preparar una forma polimorfica de la sal del acido maleico derivado de la tiazolidina-2,4-diona
CA2065986A1 (en) 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1h-indoles, intermediates and a process for their preparation, and their use as medicaments
HUP0101230A2 (hu) Eljárás 2-[(2-piridil)-metilszulfinil]-1H-benzimidazol-származékok előállítására
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
HU9400321D0 (en) New 2-[4-(4-azolyl-butyl)-1-piperazinyl] derivatives, process for producing them and pharmaceutical compositions containing them
ATE168692T1 (de) 3-substituierte cephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU2994589A (en) Novel basic-substituted 5-halo-thienoisothiazol-3-(2h)-one-1,1-dioxides, process for the preparation thereof, and pharmaceutical preparations containing these compounds
IL99777A0 (en) Indole derivatives,processes for their preparation and pharmaceutical compositions containing them
EP0301401A3 (en) Leukotriene antagonists, process for their preparation, their use in the treatment of illnesses, as well as precursors
ECSP982780A (es) Nuevo producto farmaceutico proceso para su preparacion y su uso en medicina

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees